{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:51:18Z","timestamp":1790412678235,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Foundation for Lysosomal Diseases (FEEL)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ymgme.2011.06.021","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T04:26:52Z","timestamp":1311827212000},"page":"301-307","source":"Crossref","is-referenced-by-count":39,"title":["Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease"],"prefix":"10.1016","volume":"104","author":[{"given":"Miguel-\u00c1ngel","family":"Torralba-Cabeza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n Nuviala","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Ignacio","family":"P\u00e9rez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2011.06.021_bb0005","series-title":"The Metabolic and Molecular Bases of Inheritance Disease","first-page":"3733","article-title":"Alfa galactosidase A deficiency: Fabry's disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2011.06.021_bb0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature03479","article-title":"X-inactivation profile reveals extensive variability in X-linked gene expression in females","volume":"434","author":"Carrel","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2011.06.021_bb0020","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1258\/0004563021901847","volume":"39","author":"Newman","year":"2002","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1681\/ASN.2005050545","article-title":"Cystatin C and mortality risk in the elderly: the health, aging, and body composition study","volume":"17","author":"Shlipak","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cardfail.2005.06.001","article-title":"Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure","volume":"11","author":"Arimoto","year":"2005","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0040","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa0707064","article-title":"Use of multiple biomarkers to improve the prediction of death from cardiovascular causes","volume":"358","author":"Zethelius","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/08035320600618825","article-title":"The Mainz severity score index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease","volume":"95","author":"Beck","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0060","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0065","first-page":"741","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"2010","author":"Rombach","year":"1802","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2011.06.021_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0075","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2011.06.021_bb0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10545-008-0900-3","article-title":"Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy","volume":"31","author":"Vylet'al","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.06.021_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0065-2423(09)49004-8","article-title":"Urinary biomarkers for the detection of renal injury","volume":"49","author":"Rosner","year":"2009","journal-title":"Adv. Clin. Chem."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211002083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211002083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T04:26:02Z","timestamp":1543638362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719211002083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1096719211002083"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2011.06.021","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}